130 CHF CHF 130.00
BVT-0193-M0011 mgCHF 130.00
BVT-0193-M0055 mgCHF 420.00
BVT-0193-M01010 mgCHF 755.00
|Synonyms||NSC 291308; 4,5-Dihydroxy-3-(1-propenyl)-2-cyclopenten-1-one|
|Source/Host Chemicals||Isolated from Aspergillus terreus.|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||White to off-white solid.|
|Solubility||Soluble in methanol or DMSO.|
|Identity||Determined by 1H-NMR and UV.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Protect from light.|
Stable for at least 1 year after receipt when stored at -20°C.
Store solutions at -20°C in the dark.
|Product Specification Sheet|
- Antibacterial. Phytotoxin [3, 4 , 5].
- Melanogenesis inhibitor by reducing tyrosinase production via extracellular signal-regulated protein kinase (ERK) activation [4, 5].
- Keratinocyte and epidermis proliferation inhibitor [6, 9].
- Mycotoxin .
- Anti-inflammatory modulator in pulpal inflammation .
- Angiogenesis inhibitor through angiogenin secretion inhibition .
- Collagen-induced platelet aggregation inhibitor .
- Antioxidant agent that enhances osseointegration by decreasing the level of ROS and having a potentially synergistic effect on osteoblast differentiation .
- Proteasome inhibitor [12, 14].
- Studies in the biochemistry of micro-organisms: The metabolic products of Aspergillus terreus Thom. A new mould metabolic product-terrein: H. Raistrick & G. Smith; Biochem. J. 29, 606 (1935)
- The constitution and stereochemistry of Terrein: D.H.R. Barton & E. Miller; J. Chem. Soc. 1955, 1028 (1955)
- Bioactive metabolites from a marine-derived strain of the fungus Emericella variecolor: J. Malmstrom, et al.; J. Nat. Prod. 65, 364 (2002)
- Terrein: a new melanogenesis inhibitor and its mechanism: S.H. Park, et al.; Cell Mol. Life Sci. 61, 2878 (2004)
- Synthesis and melanin biosynthesis inhibitory activity of (+/-)-terrein produced by Penicillium sp. 20135: S. Lee, et al.; Bioorg. Med. Chem. Lett. 15, 471 (2005)
- Terrein, a fungal metabolite, inhibits the epidermal proliferation of skin equivatents: D.S. Kim, et al.; J. Dermatol. Sci. 46, 65 (2007)
- Production of mycotoxins by Aspergillus lentulus and other medically important and closely related species in section Fumigati: T. O. Larsen, et al.; Med. Mycol. 45, 225 (2007)
- Terrein reduces pulpal inflammation in human dental pulp cells: J.C. Lee, et al.; J. Endod. 34, 433 (2008)
- Terrein inhibits keratinocyte proliferation via ERK inactivation and G2/M cell cycle arrest: D.S. Kim, et al.; Exp. Dermatol. 17, 312 (2008)
- A new terrein glucoside, a novel inhibitor of angiogenin secretion in tumor angiogenesis: M. Arakawa, et al.; J. Antibiot. (Tokyo) 61, 442 (2008)
- Inhibitory effects of dihydroterrein and terrein isolated from Aspergillus novofumigatus on platelet aggregation: T. Hosoe, et al.; Mycotoxins 59, 75 (2009)
- Long-term suppression of tyrosinase by terrein via tyrosinase degradation and its decreased expression: S.H. Park, et al.; Exp. Dermatol. 18, 562 (2009)
- Enhancement of osteoblast biocompatibility on titanium surface with Terrein treatment: Y.H. Lee, et al.; Cell. Biochem. Funct. 28, 678 (2010)
- Studies on terrein as a new class of proteasome inhibitors: M. Demasi, et al.; J. Braz. Chem. Soc. 21, 299 (2010)